Trainees’ “Must-See” at the 2017 ASH Annual Meeting

With the 59th ASH Annual Meeting and Exposition right around the corner, we asked the members of the Trainee Council which sessions (aside from the trainee sessions of course) were on their “can’t miss” list. Here’s how they responded:

“I am looking forward to the ‘How I Treat’ sessions relating to hemostasis and thrombosis such as ‘How Long to Anticoagulate My Patient with Acute VTE’ on Saturday. Trainees should make every effort to attend these educational sessions within their interest area, as they are always taught by the experts and include the newest data.” – Hanny Al-Samkira, MD

“As a second-year fellow interested in lymphoma, I can’t wait to attend oral abstract 623, ‘Mantle cell, Follicular, and Other Indolent B-Cell Lymphoma- Clinical Studies: Mantle Cell Lymphoma, New Therapies’ to hear the newest data in this area.” – Puja Arora, MD

“The scientific sessions on hematologic diseases, specifically ‘Clonal Evolution in Myeloid Malignancies’ are a must-see on my list, to learn about the latest progress made in understanding the mechanism of leukemia development.” – Shruti Bhatt, PhD

“As a second-year fellow interested in transitions in nonmalignant hematology, I am interested in the education sessions on sickle cell quality improvement to learn about high-quality models of care for a population who deserves it.” – Alex Boucher, MD

“As a second-year fellow interested in lymphoma, the education session ‘Evolving Strategies in Aggressive B-Cell Lymphoma’ focused on lymphoma biology, novel agents, and tailored therapeutic strategies is a must!” – Jaime Gastwirt, MD

“As a third-year fellow interested in acute lymphoblastic leukemia, the education session ‘Acute Lymphocytic Leukemia: New Approaches in Management’ sounds very exciting. Additionally, I’m looking forward to the Networking Reception for Female Hematologists.” – Leidy L. Isenalumhe, MD, MS

“As a third-year fellow interested in cancer associated thrombosis, the education session ‘Common Clinical Questions in Cancer-Associated Venous Thromboembolism’ sounds fascinating.” – Ang Li, MD

“As a third-year fellow in pediatric hematology/oncology with an interest in immunotherapy, I can’t wait to attend ‘The Expanding Role of Immunotherapy in Non-Hodgkin Lymphoma’ at the annual meeting.” – Scott Moerdler, MD

“As a third-year fellow interested in delivering high-quality patient care, I am looking forward to the session ‘Effective Implementation of Evidence-Based Pathways and Clinical Guidelines’ at this year’s annual meeting.” – Deva Sharma, MD

“As a third-year fellow interested in plasma cell disorders, I am excited about the education session 'Controversies in Myeloma' at the annual meeting.” – Surbhi Sidana, MD

“As a second-year fellow interested in cancer informatics, I will be at the session ‘Next Generation Sequencing (NGS) in Routine Diagnostics - Are we there yet?’ This session will highlight the spectrum of NGS testing and how to leverage the large data into meaningful treatment decisions for our patients.” – Arun Singavi, MD

“As a postdoctoral fellow interested in the chromatin biology of healthy and malignant hematopoietic cells, the ‘Novel Epigenetic Modifications in Cancer and Development’ session is a must! TETs, IDH1/2, and RNA methylation are hot topics in hematopoiesis right now, and Drs. Figueroa, Rao, and Lyko are some of the major movers and shakers in the field.” – Andrew Volk, PhD

Follow us on Twitter @ash_hematology and use the official hashtag #ASH17. Share your annual meeting experience using #ASHTrainee.